Massive lung cancer database aims to unlock future treatments
NCT ID NCT05267041
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is building a large database of blood samples, tumor samples, and scans from 4,000 people with lung cancer. Researchers will follow participants for up to 10 years to collect information that can help future studies. The goal is to better understand lung cancer and improve care, but this study does not test any new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 4,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
May 2042
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient treated for a thoracic cancer in the Lyon University Hospital: non-small cell lung cancer, small cell lung cancer, mesothelioma… * Diagnosis can be done: * By cytology or pathologic assessment * Or by multidisciplinary team meeting decision: * Irradiation without morpho-metabolic sampling * Treatment without sampling based on non-invasive molecular data Exclusion Criteria: \- Refusal to participate For optional blood sampling : * \< 30 kg for blood collection * No blood sampling schedule for care
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Hospitalier Lyon Sud
RECRUITINGPierre-Bénite, 69495, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- New PET tracer aims to light up hidden cancer targets
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- Breath-Tracking sensor aims to sharpen lung cancer scans